Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Banco Santander, S.A.
  6. News
  7. Summary
    SAN   ES0113900J37


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Banco Santander S A : Santander funds CNIC project that finds solution to boost Covid-19 vaccine efficacy

12/01/2021 | 03:51am EST

The research, co-led by Dr David Sancho, scientists from IdiPAZ (Hospital La Paz research institute) and CNB-CSIC (National Centre for Biotechnology), had the backing of Banco Santander through its Fondo Solidario Juntos (Solidarity fund), which supports solutions to the pandemic.

Dr David Sancho: "Immunotherapy with MV130 will help boost the efficacy of vaccines, especially in certain groups and against variants that are more resistant to inoculation".

Madrid, 30 November 2021.
Research led by Dr David Sancho of the Spanish National Center for Cardiovascular Research (CNIC) and funded by Banco Santander through its Fondo Solidario Juntos (created in 2020 to support initiatives in the fight against the pandemic) has found that MV130, an immunotherapy based on nasal injection of an inactive bacterium, prevents death by coronavirus SARS-CoV-2 in animals and boosts the efficacy of Covid-19 vaccines.

This form of immunotherapy primes the innate immune system by inducing epigenetic changes in innate immune cells, as Dr Sancho (CNIC head of Immunobiology) has shown in other trials.

Vaccines "train" the immune system to combat the virus through the so-called "immune memory". Until a few years ago, it was thought that adaptive immunity was the only type that had a memory (the ability to recognize pathogens - viruses, bacteria, etc. - and send a response to protect cells), while innate immunity (non-specific) did not: "We now know that we can 'train' innate immunity to trigger a better response to new, unrelated infections, like with bacteria to protect against viral infections such as SARS-CoV-2. What's more, such training will stand the test of time", Dr Sancho explained.

That's why, he says, "strengthening the innate immune system with MV130 will bolster Covid-19 vaccines".

MV130 was developed by Spanish company Immunotek, S.L. It contains several inactive bacteria and has proven effective in clinical trials on adults and children with chronic respiratory diseases. The latest trials that Banco Santander is co-financing show that it can be used against viral infections like SARS-CoV-2 in animals and, therefore, can boost the vaccines' ability to trigger an immune response.

The project, financed by Banco Santander and also involving researchers from IdiPAZ and CNB-CSIC, lasted just over a year and is a significant breakthrough in the fight against coronavirus, which is showing no signs of disappearing fast.


Banco Santander SA published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2021 08:50:07 UTC.

© Publicnow 2021
All news about BANCO SANTANDER, S.A.
01/21Santander's US Unit Extends Tender Offer for Remaining Shares of Santander Consumer USA..
01/21Early Redemption Notice Series 1137
01/21Banco Santander Unit Extends Tender Offer for Remaining Shares of Santander Consumer US..
01/21Fitch Affirms Santander UK Group Holdings at 'A'/Stable
01/20SANTANDER : Credit Suisse remains Neutral
01/20BANCO SANTANDER S A : Santander Spain, second company in the world with best employee cond..
01/20Fitch Rates Santander Retail Auto Lease Trust 2022-A
01/19SANTANDER : Jefferies gives a Neutral rating
01/19BANCO SANTANDER S A : Santander and the British Council offer 5,000 online scholarships to..
01/19BANCO SANTANDER S A : Santander acquires 30% stake in Atempo Growth to boost funding for E..
More news
Analyst Recommendations on BANCO SANTANDER, S.A.
More recommendations
Sales 2021 46 214 M 52 420 M 52 420 M
Net income 2021 7 839 M 8 892 M 8 892 M
Net Debt 2021 - - -
P/E ratio 2021 6,74x
Yield 2021 4,04%
Capitalization 52 622 M 59 682 M 59 689 M
Capi. / Sales 2021 1,14x
Capi. / Sales 2022 1,10x
Nbr of Employees 193 303
Free-Float 99,2%
Duration : Period :
Banco Santander, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BANCO SANTANDER, S.A.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 3,08 €
Average target price 3,90 €
Spread / Average Target 26,4%
EPS Revisions
Managers and Directors
José Antonio Álvarez Álvarez Vice Chairman & Chief Executive Officer
José Antonio García Cantera Chief Financial Officer & Senior Vice President
Ana Patricia Botín-Sanz de Sautuola O'Shea Executive Chairman
Dirk Ludwig Marzluf Chief Operating & Technical Officer
Marjolein van Hellemondt-Gerdingh Group Chief Compliance Officer
Sector and Competitors